Vertex begins phase 3 studies of VX─445, tezacaftor & ivacaftor as triple combo regimen for people with CF

Vertex Pharmaceuticals Incorporated announced that it is initiating two phase 3 studies of VX─445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF). The first

More From BioPortfolio on "Vertex begins phase 3 studies of VX─445, tezacaftor & ivacaftor as triple combo regimen for people with CF"